These data support the increasing concern that S protein-based candidate vaccines are not harnessing the full potential of human anti-SARS-CoV-2 T cell immunity, especially since diversity of T cell responses was associated with mild/asymptomatic COVID-19 and they are vital for long-term immunity. Here, PROS1 is linked to COVID-19.